PAVmed Inc. (PAVM) Q3 2024 Earnings Call Transcript Summary
PAVmed Inc. (PAVM) Q3 2024 Earnings Call Transcript Summary
They are working towards maintaining NASDAQ listing with a plan that involves restructuring convertible debt into Series C convertible preferred stock to address the financial deficit and achieve compliance with NASDAQ's continued listing standards.The following is a summary of the PAVmed Inc. (PAVM) Q3 2024 Earnings Call Transcript:
以下是PAVmed Inc.（pavmed）2024年第三季度業績會的摘要：
Financial Performance:
財務業績：
PAVmed reported a transformational quarter with strategic corporate restructuring to solidify its financial position, including the deconsolidation of Lucid Diagnostics and restructuring of convertible debt.
Notably, they accomplished a reduction in the shareholder deficit by half due to the deconsolidation of Lucid from PAVmed's financials.
They are working towards maintaining NASDAQ listing with a plan that involves restructuring convertible debt into Series C convertible preferred stock to address the financial deficit and achieve compliance with NASDAQ's continued listing standards.
PAVmed報告了一個變革性季度，進行了戰略性企業重組，鞏固了其財務狀況，包括解除對Lucid Diagnostics的關聯狀態以及重組可轉換債務。
值得注意的是，他們通過解除對Lucid Diagnostics的關聯狀態，成功將股東赤字減少了一半。
他們正在努力維持在納斯達克的上市地位，制定了一項計劃，將可轉換債務重組爲C系列可轉換優先股，以解決財務赤字並達到符合納斯達克持續上市標準的要求。
Business Progress:
業務進展：
Veris Health completed a pilot with The Ohio State University's James Cancer Center, focusing on cancer care, and is discussing long-term commercial partnerships.
Lucid Diagnostics reported record revenue in Q3 and is expanding its direct contracting in concierge medicine and employer markets.
The company is actively seeking funding for its subsidiaries to further develop their respective technologies, including Veris Health's Cancer Care Platform and the PortIO technology through PMX incubator.
Veris Health與俄亥俄州立大學詹姆斯癌症中心合作完成了一項試點項目，專注於癌症護理，並討論長期的商業合作伙伴關係。
Lucid Diagnostics在第三季度報告了創紀錄的營業收入，並在醫療保健服務和僱主市場擴大了其直接合同。
公司正積極尋求爲其子公司籌集資金，以進一步開發各自的技術，包括Veris Health的Cancer Care Platform和通過PMX孵化器開發的PortIO技術。
Opportunities:
機會：
PAVmed's corporate restructuring has positioned it as a sustainable, diversified commercial life sciences company with multiple independently financed subsidiaries operating under a shared services model.
Expansion of Lucid's direct contracting initiative and new developments in Veris Health's digital health platform indicate potential growth areas.
pavmed的企業重組將其定位爲可持續發展、多元化的商業生命科學公司，其多個獨立融資子公司在共享服務模式下運營。
Lucid直接合同計劃的擴張以及Veris Health數字健康平台的新發展表明潛在的增長領域。
Risks:
風險：
Delay in financing and restructuring could affect the progress of Veris Health's FDA submission timeline and the development of the PortIO technology.
Ensuring continuous NASDAQ listing through shareholder approval for restructuring convertible debt is critical.
融資和重組的延遲可能影響Veris Health的FDA提交時間表和PortIO技術的開發進度。
通過股東批准重組可轉換債務以確保納斯達克上市連續性至關重要。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
